Tag Directory / PHARMACEUTICALS     showing 101–120 of 120


FDA approves all ages gene therapy for spinal condition / Beckers

Ella Jeffries / beckershospitalreview - The FDA approved Novartis’ Itvisma (onasemnogene abeparvovec-brve), the company’s first and only gene replacement therapy for spinal muscular atrophy in children 2 and older, as well as for teens and adults. The therapy is designed to address the genetic …

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda

FDA approves all ages gene therapy for spinal condition

3 months / beckershospitalreview / Ella Jeffries

FDA approves Novartis’ Itvisma for older patients with spinal muscular atrophy

3 months / endpoints / Ayisha Sharma

Monday, December 1, 2025, 4:21 am / permalink 16428 / 2 stories in 3 months


Novo submits high-dose Wegovy for FDA approval using voucher / Endpoints

Max Bayer / endpoints - Novo Nordisk submitted a higher dose of its obesity drug Wegovy for FDA approval and is using a recently-won voucher to expedite the review. The company said Wednesday that it submitted ...

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #publichealth #biotech #drugdevelopment #fda

Novo Nordisk seeks FDA approval of higher-dose Wegovy

3 months / beckershospitalreview / Paige Twenter

Novo submits high-dose Wegovy for FDA approval using voucher

3 months / endpoints / Max Bayer

Saturday, November 29, 2025, 5:21 pm / permalink 16400 / 2 stories in 3 months


CASSANDRA-PACT-21 Trial Update: Preoperative PAXG vs mFOLFIRINOX in Resectable and Borderline Resectable PDAC / OncoDaily

oncodaily - The landscape of early-stage pancreatic ductal adenocarcinoma (PDAC) continues to evolve as clinicians move from surgery-first strategies toward perioperative treatment. Neoadjuvant and perioperative approaches have shown growing promise, yet no […]

#healthcare #pharmaceuticals #publichealth #drugdevelopment

Advancing and Learning More About New Treatments for Pancreatic Cancer Every Day – Dana-Farber Cancer Institute

3 months / oncodaily

Yan Leyfman: New Advances in Pancreatic Cancer Immunotherapy

3 months / oncodaily

Allogeneic Stem Cell–Engineered Mesothelin-Redirected CAR-NKT Cells for Orthotopic and Metastatic Pancreatic Cancer

3 months / oncodaily

CASSANDRA-PACT-21 Trial Update: Preoperative PAXG vs mFOLFIRINOX in Resectable and Borderline Resectable PDAC

3 months / oncodaily

Neoadjuvant Quadruplet PAXG Regimen Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable PDAC

3 months / esmo

Saturday, November 29, 2025, 9:21 am / permalink 16387 / 5 stories in 3 months


Novo Nordisk GLP-1 fails to slow Alzheimer’s in trials / Beckers

Ella Jeffries / beckershospitalreview - Novo Nordisk’s GLP-1 drug semaglutide did not demonstrate a statistically significant effect in slowing progression of Alzheimer’s disease in two late-stage clinical trials. According to a Nov. 24 news release from the company, two double-blinded, placebo…

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #publichealth #biotech #drugdevelopment

CMS unveils negotiated prices for Ozempic, Wegovy and other drugs from second round of IRA talks

3 months / endpoints / Nicole DeFeudis

Postpartum Prescription of GLP-1 Drugs Has Increased Sharply, Study Finds

3 months / nytimes / Roni Caryn Rabin

Novo Nordisk GLP-1 fails to slow Alzheimer’s in trials

3 months / beckershospitalreview / Ella Jeffries

Pill form of semaglutide fails to slow Alzheimer's in large trial

3 months / medicalxpress

Ozempic Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials

3 months / nytimes / Gina Kolata

Tuesday, November 25, 2025, 10:21 am / permalink 16294 / 5 stories in 3 months


FDA Approves Pembrolizumab + Enfortumab Vedotin-ejfv for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer / OncoDaily

oncodaily - What Does FDA Approval Mean? The U.S. Food and Drug Administration (FDA) evaluates new cancer therapies to determine whether they are safe and effective for clinical use. Approval is based […]

#healthcare #pharmaceuticals #publichealth #drugdevelopment #fda

FDA approves new bladder cancer treatment

3 months / beckershospitalreview / Ella Jeffries

FDA Approves Pembrolizumab + Enfortumab Vedotin-ejfv for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

3 months / oncodaily

Monday, November 24, 2025, 10:23 am / permalink 16257 / 2 stories in 3 months


New nasal nanodrops wipe out brain tumors in mice / Science Daily Cancer

sciencedaily - A new nasal-delivered nanotherapy shows promise against aggressive glioblastoma tumors. By activating the STING immune pathway using gold-core spherical nucleic acids, researchers were able to reach the brain without invasive surgery. When paired with dru…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

Fatma Nihan Akkoc Mustafayev: Honored to Give an Oral Presentation on Hispanic GBM Outcomes at SNO2025

3 months / oncodaily

New nasal nanodrops wipe out brain tumors in mice

3 months / sciencedaily

Nasal nanomedicine delivers immune-boosting therapy to fight brain tumors

3 months / medicalxpress

Saturday, November 22, 2025, 1:21 pm / permalink 16217 / 3 stories in 3 months


FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation / ESMO

esmo - Evidence for efficacy is based on the results from the KO-MEN-001 study

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda

FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation

3 months / esmo

FDA Approves Ziftomenib (Komzifti) for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

3 months / oncodaily

Saturday, November 22, 2025, 9:22 am / permalink 16210 / 2 stories in 3 months


Novo Nordisk rolls out lower prices for Ozempic and Wegovy / Medical Express

medicalxpress - People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.

#obesity #healthcare #pharmaceuticals #drugpricing #novonordisk #weightloss #publichealth #biotech

When Drug Price Transparency Isn’t Enough

3 months / thehealthcareblog / matthew holt

Q&A: Navigating weight loss—when to consider bariatric surgery after GLP-1 therapy

3 months / medicalxpress

Daily pill could offer alternative to weight-loss injections

3 months / newscientist

Novo Nordisk rolls out lower prices for Ozempic and Wegovy

3 months / medicalxpress

Novo Nordisk lowers self-pay prices for weight loss drugs ahead of Lilly, TrumpRx

3 months / endpoints / Zachary Brennan

Ozempic, Wegovy to be sold at $199 a month for new patients

3 months / beckershospitalreview / Paige Twenter

Thursday, November 20, 2025, 1:22 am / permalink 16131 / 6 stories in 3 months


Mikael Dolsten removes himself from board candidacy at Novo; Bavarian Nordic chairman resigns / Endpoints

Alex Hoffman / endpoints - → In what appears to be another blow to Novo Nordisk, ex-Pfizer CSO Mikael Dolsten has withdrawn his nomination to join the company's board of directors due to ...

#healthcare #pharmaceuticals #publichealth #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment

Merck Makes Big Antiviral Move With $9B Deal to Land Cidara’s Late-Stage Drug for Flu Prevention

4 months / medcitynews / Frank Vinluan

Mikael Dolsten removes himself from board candidacy at Novo; Bavarian Nordic chairman resigns

4 months / endpoints / Alex Hoffman

Saturday, November 15, 2025, 3:21 pm / permalink 16003 / 2 stories in 4 months


F.D.A. Will Remove Black Box Warnings From Hormone Treatments for Menopause / NYT

Roni Caryn Rabin / nytimes - The benefits of hormone replacement have been underappreciated, Dr. Marty Makary, the agency’s commissioner, said on Monday. Critics described evidence for the change as insufficient.

#healthcare #pharmaceuticals #publichealth #governmentpolicy #fda

FDA lifts major warnings on hormone replacement therapy

4 months / medicalxpress

FDA to remove safety warnings on hormonal menopause therapy

4 months / healthcaredive / Delilah Alvarado

F.D.A. Will Remove Black Box Warnings From Hormone Treatments for Menopause

4 months / nytimes / Roni Caryn Rabin

Saturday, November 15, 2025, 10:21 am / permalink 15996 / 3 stories in 4 months


FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths / ABC News

go - The Food and Drug Administration is adding a new warning to a gene therapy linked to two patient deaths earlier this year

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda

US narrows use of muscle-wasting therapy after teen deaths

4 months / medicalxpress

FDA updates Sarepta’s Duchenne gene therapy label, requests postmarketing study

4 months / endpoints / Lei Lei Wu

FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths

4 months / go

Saturday, November 15, 2025, 5:21 am / permalink 15991 / 3 stories in 4 months


Richard Pazdur Appointed Director of the FDA’s Drug Center: A New Chapter for Cancer Regulation / OncoDaily

oncodaily - Dr. Richard Pazdur, one of the most influential figures in oncology drug regulation, has been appointed Director of the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and […]

#healthcare #pharmaceuticals #publichealth #governmentpolicy #drugdevelopment #fda

FDA announces new regulatory pathway for personalized rare disease therapies

4 months / endpoints / Jared Whitlock

Pazdur vs. Prasad: Can the CDER-CBER dynamic change under new leadership?

4 months / endpoints / Zachary Brennan

Patrick Soon-Shiong: Expanded Access is Not Enough… Withholding FDA Approval Impacts Quality Care

4 months / oncodaily

Richard Pazdur, longtime FDA oncology leader, to head agency’s main drug office

4 months / healthcaredive / Kristin Jensen

FDA taps longtime oncology lead as drug center chief

4 months / beckershospitalreview / Ella Jeffries

Richard Pazdur Appointed Director of the FDA’s Drug Center: A New Chapter for Cancer Regulation

4 months / oncodaily

F.D.A. Names Agency Veteran to Run Drug Division

4 months / nytimes / Christina Jewett and Rebecca Robbins

FDA taps Richard Pazdur as new CDER director after Tidmarsh's resignation

4 months / endpoints / Alexis Kramer

Wednesday, November 12, 2025, 6:22 am / permalink 15886 / 8 stories in 4 months


FDA rolls back warning labels on HRT products for menopause, citing misinformation / Fierce

fiercehealthcare - The action, announced Monday, follows a comprehensive review of scientific literature by an expert panel at the agency in July, as well as a public comment period, officials said. Pharmas are expected to update and reprint their product labeling to remove…

#healthcare #pharmaceuticals #publichealth #governmentpolicy

FDA Will Remove Warnings for HRT Products Used for Menopause

4 months / medcitynews / Marissa Plescia

FDA to remove boxed warnings from hormone therapy for menopause

4 months / beckershospitalreview / Ella Jeffries

The FDA removes a long-standing warning from hormone-based menopause drugs

4 months / medicalxpress

FDA seeks to remove warnings from labels of hormone therapies for menopause

4 months / endpoints / Zachary Brennan

FDA rolls back warning labels on HRT products for menopause, citing misinformation

4 months / fiercehealthcare

Monday, November 10, 2025, 5:24 pm / permalink 15854 / 5 stories in 4 months


Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera / MedCity

Frank Vinluan / medcitynews - Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo Nordisk was willing to pay. The financial consideration and the greater certainly of a deal close tipped the balance in Pfizer’s favo…

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #pfizer #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment

Pfizer prevails in $10B bidding war for Metsera

4 months / beckershospitalreview / Ella Jeffries

Ex-Lilly Diabetes leaders hunt for new obesity drugs at VC firm

4 months / endpoints / Kyle LaHucik

Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera

4 months / medcitynews / Frank Vinluan

Novo Nordisk, Pfizer make personnel waves as they squabble over Metsera

4 months / endpoints / Alex Hoffman

Monday, November 10, 2025, 12:21 am / permalink 15823 / 4 stories in 4 months


Pfizer poised to buy Metsera in $10 bn deal after bidding war / Medical Express

medicalxpress - Pfizer was poised to seal a takeover of Metsera on Saturday after its improved offer won over the biotechnology startup's board and Danish challenger Novo Nordisk called a halt to a back-and-forth bidding war.

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #pfizer #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment

Pfizer poised to buy Metsera in $10 bn deal after bidding war

4 months / medicalxpress

Novo Nordisk raises Metsera bid again, hoping to top Pfizer's latest offer

4 months / endpoints / Drew Armstrong

Saturday, November 8, 2025, 3:21 pm / permalink 15805 / 2 stories in 4 months


#AHA25: Amgen’s cholesterol drug cuts first-time cardiovascular events by a quarter / Endpoints

Elizabeth Cairns / endpoints - Amgen on Saturday said its cholesterol-lowering drug Repatha cut cardiovascular events by 25% when added on top of standard therapy in high-risk patients who have never had a heart attack or stroke. Repatha is already ...

#healthcare #pharmaceuticals #publichealth

Fat tissue around the heart may contribute to greater heart injury after a heart attack

3 months / medicalxpress

Uterine fibroids linked to elevated heart disease risk

3 months / medicalxpress

4 months / hcplive

4 months / hcplive

4 months / hcplive

4 months / hcplive

Merck PCSK9 Pill Results Point to Extremely Low Cholesterol Future

4 months / nytimes / Gina Kolata

Coronary artery calcium may be a predictor for all-cause mortality, including non-cardiac conditions

4 months / medicalxpress

Minimally invasive coronary calcium CT scans measuring heart disease risk can find other potential health problems

4 months / medicalxpress

4 months / hcplive

#AHA25: Amgen’s cholesterol drug cuts first-time cardiovascular events by a quarter

4 months / endpoints / Elizabeth Cairns

Avirup Guha: Leading Insights in Cardio-Oncology to be Presented at AHA25 in New Orleans

4 months / oncodaily

Avirup Guha: Key Cardio-Oncology Sessions at AHA25

4 months / oncodaily

Saturday, November 8, 2025, 9:21 am / permalink 15793 / 13 stories in 4 months


FDA approves J&J’s Darzalex for smoldering multiple myeloma / Endpoints

Lei Lei Wu / endpoints - The FDA on Thursday approved Johnson & Johnson’s Darzalex injection for high-risk smoldering multiple myeloma, a condition in which people have abnormal cells that could turn into myeloma but don’t have ...

#healthcare #pharmaceuticals #publichealth

FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma

4 months / oncodaily

4 months / targetedonc

FDA approves J&J’s Darzalex for smoldering multiple myeloma

4 months / endpoints / Lei Lei Wu

Saturday, November 8, 2025, 12:21 am / permalink 15786 / 3 stories in 4 months


Patient in Intellia CRISPR trial dies after being hospitalized with liver injury / Endpoints

Ryan Cross / endpoints - A man in his early 80s who was recently hospitalized with liver injury, a few weeks after receiving an experimental gene editing therapy, died on Wednesday ...

#healthcare #pharmaceuticals #publichealth

Intellia trial participant dies after severe liver reaction 

4 months / beckershospitalreview / Ella Jeffries

Patient in Intellia CRISPR trial dies after being hospitalized with liver injury

4 months / endpoints / Ryan Cross

Saturday, November 8, 2025, 12:21 am / permalink 15784 / 2 stories in 4 months


CMS unveils new Medicaid drug payment model / Endpoints

Max Bayer / endpoints - CMS plans to launch a new drug payment model for state Medicaid programs, the first of potentially multiple pricing models under President Donald Trump's "most favored nation" push that the pharma industry has been closely ...

#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy

White House unveils MFN deals; Metsera saga ends; Q3 earnings updates; and more

4 months / endpoints / Max Gelman

CMS unveils new Medicaid drug payment model

4 months / endpoints / Max Bayer

CMS unveils new model to bring most-favored nation pricing to Medicaid

4 months / fiercehealthcare

Saturday, November 8, 2025, 12:21 am / permalink 15785 / 3 stories in 4 months


What Trump’s New Drug Pricing Deal Means for People With Obesity / NYT

Rebecca Robbins, Dani Blum and Margot Sanger-Katz / nytimes - The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

#trumpadministration #obesity #healthcare #pharmaceuticals #drugpricing #elililly #novonordisk #weightloss #publichealth #governmentpolicy

Pfizer triumphs over Novo Nordisk with $10B bid for Metsera

4 months / endpoints / Elizabeth Cairns

Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal

4 months / nytimes / Francesca Regalado

White House strikes new deals to lower prices on obesity drugs for some

4 months / npr / Sydney Lupkin

Trump Announces Deal to Drop Obesity Drug Prices to as Little as $149 a Month

4 months / nytimes / Rebecca Robbins, Margot Sanger-Katz and Dani Blum

What Trump’s New Drug Pricing Deal Means for People With Obesity

4 months / nytimes / Rebecca Robbins, Dani Blum and Margot Sanger-Katz

Eli Lilly, Novo Nordisk strike deals with White House to cut prices of weight loss drugs

4 months / fiercehealthcare

Friday, November 7, 2025, 11:57 pm / permalink 15780 / 6 stories in 4 months


Back to Top


PHARMACEUTICALS Heatmap

90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.



More Top Stories...

FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...


NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.